Format

Send to

Choose Destination
BMC Vet Res. 2016 Mar 10;12:49. doi: 10.1186/s12917-016-0676-x.

Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial.

Author information

1
R&D Bioiberica SA, Pça. Francesc Macià 7, 08029, Barcelona, Spain. ssegarra@bioiberica.com.
2
Interlab-UMU, Campus de Excelencia "Mare Nostrum", University of Murcia, Campus Espinardo, 30071, Murcia, Spain.
3
Centre de Recerca en Sanitat Animal (CReSA), IRTA, Campus de la Universitat Autònoma de Barcelona, 08193, Bellaterra, Cerdanyola del Vallès, Spain.
4
R&D Bioiberica SA, Pça. Francesc Macià 7, 08029, Barcelona, Spain.
5
Department of Animal Medicine and Surgery, Faculty of Veterinary Science, Complutense University of Madrid (UCM), 28040, Madrid, Spain.
6
Department of Animal Medicine and Surgery, Faculty of Veterinary Science, and Health Surveillance Centre (VISAVET), Complutense University of Madrid (UCM), 28040, Madrid, Spain.
7
Department of Veterinary Clinical Sciences and Services, Royal Veterinary College, University of London, Hatfield, Hertfordshire, EN6 1NB, UK.

Abstract

BACKGROUND:

Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing chondroitin sulfate (CS) and prebiotics (resistant starch, β-glucans and mannaoligosaccharides) was developed to target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180 days administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut microbiota, and serum biomarkers of inflammation and oxidative stress.

RESULTS:

Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant differences between groups (p > 0.05) for any of the studied parameters. Final data analysis (supplement: n = 9; placebo: n = 10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after treatment (p < 0.001). After treatment, a significant decrease (1.53-fold; p < 0.01) in histologic score was seen only in the supplement group. When groups were compared, the supplement group showed significantly higher serum cholesterol (p < 0.05) and paraoxonase-1 (PON1) levels after 60 days of treatment (p < 0.01), and the placebo group showed significantly reduced serum total antioxidant capacity (TAC) levels after 120 days (p < 0.05). No significant differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group.

CONCLUSIONS:

The combined administration of the supplement with hydrolyzed diet over 180 days was safe and induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to dietary treatment of this supplement on intestinal histology and CIBDAI.

KEYWORDS:

CIBDAI; Chronic enteropathy; Dog; Glycosaminoglycan; Oxidative stress; Resistant starch; β-glucans

PMID:
26965834
PMCID:
PMC4785639
DOI:
10.1186/s12917-016-0676-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center